United Therapeutics Corp UTHR.OQ UTHR.O is expected to show a rise in quarterly revenue when it reports results on February 26 for the period ending December 31 2024
The Silver Spring Maryland-based company is expected to report a 19.5% increase in revenue to $734.74 million from $614.7 million a year ago, according to the mean estimate from 11 analysts, based on LSEG data.
LSEG's mean analyst estimate for United Therapeutics Corp is for earnings of $6.31 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 5 "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for United Therapeutics Corp is $395.00, above its last closing price of $361.10.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | 6.32 | 6.42 | 6.39 | Missed | -0.5 |
Jun. 30 2024 | 6.48 | 6.40 | 5.85 | Missed | -8.6 |
Mar. 31 2024 | 5.70 | 5.65 | 6.17 | Beat | 9.2 |
Dec. 31 2023 | 4.09 | 4.19 | 4.36 | Beat | 4.2 |
Sep. 30 2023 | 5.04 | 5.04 | 5.38 | Beat | 6.7 |
Jun. 30 2023 | 4.49 | 4.51 | 5.24 | Beat | 16.3 |
Mar. 31 2023 | 4.41 | 4.52 | 4.86 | Beat | 7.4 |
Dec. 31 2022 | 4.54 | 4.51 | 2.67 | Missed | -40.8 |
This summary was machine generated February 24 at 13:54 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。